Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 11:17:2055-2063.
doi: 10.2147/IJGM.S460305. eCollection 2024.

Statin-Associated Liver Dysfunction and Muscle Injury: epidemiology, Mechanisms, and Management Strategies

Ming-Ming Ma #  1 , Yao-Yao Xu #  2 , Li-Hua Sun #  1 , Wen-Jie Cui  1 , Miao Fan  3 , Su Zhang  4 , Lei Liu  5 , Ling-Zhi Wu  6 , Liu-Cheng Li  7
Affiliations
Review

Statin-Associated Liver Dysfunction and Muscle Injury: epidemiology, Mechanisms, and Management Strategies

Ming-Ming Ma et al. Int J Gen Med. .

Abstract

Surveillance of drug safety is an important aspect in the routine medical care. Adverse events caused by real-world drug utilization has become one of the leading causes of death and an urgent issue in the field of toxicology. Cardiovascular disease is now the leading cause of fatal diseases in most countries, especially in the elderly population who often suffer from multiple diseases and need long-term multidrug therapy. Among which, statins have been widely used to lower bad cholesterol and regress coronary plaque mainly in patients with hyperlipidemia and atherosclerotic cardiovascular diseases (ASCVD). Although the real-world benefits of statins are significant, different degrees and types of adverse drug reactions (ADR) such as liver dysfunction and muscle injury, have a great impact on the original treatment regimens as well as the quality of life. This review describes the epidemiology, mechanisms, early identification and post-intervention of statin-associated liver dysfunction and muscle injury based on the updated clinical evidence. It provides systematic and comprehensive guidance and necessary supplement for the clinical safety of statin use in cardiovascular diseases.

Keywords: cardiovascular diseases; countermeasures; liver dysfunction; muscle injury; statin.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Early identification of risk factors (A) and intervention strategies (B) for statin-related muscle injury.
Figure 2
Figure 2
Countermeasures of liver dysfunction caused by statins.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sun L, Zhao Q, Wang Y, et al. Efficacy and safety of anlotinib-containing regimens in advanced non-small cell lung cancer: a real-world study. Int J Gen Med. 2023;16:4165–4179. doi:10.2147/IJGM.S424777 - DOI - PMC - PubMed
    1. Tchio-Nighie KH, Mpoh MM, Tchokomeni H, et al. Drug safety monitoring in health programs of Cameroon. J Pharmacovigil. 2022;10(9):10000385. - PMC - PubMed
    1. Zhang XJ, Zhou JG, Pan M, Yuan W, Gao B. Analysis of adverse drug reaction reports from a public hospital in Shanxi Province in 2022. Risk Manag Healthc Policy. 2023;16:1391–1401. doi:10.2147/RMHP.S418386 - DOI - PMC - PubMed
    1. Liu S, Li Y, Zeng X, et al. Burden of cardiovascular diseases in China, 1990–2016: findings from the 2016 global burden of disease study. JAMA Cardiol. 2019;4(4):342–352. doi:10.1001/jamacardio.2019.0295 - DOI - PMC - PubMed
    1. Wang X, Li J, Wang T, et al. Associations between statins and adverse events in secondary prevention of cardiovascular disease: pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials. Front Cardiovasc Med. 2022;9:929020. doi:10.3389/fcvm.2022.929020 - DOI - PMC - PubMed